Post on 16-Dec-2015
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
PathoGenoMicsERA-NET
WP 2 Policy maker workshop of common understanding:
Survey on the national programmes
7th April 2005, Bonn
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
9/04 9/06 9/099/089/05 9/07
WP 3 FR Strategic and analytic activities
WP 4 FR Economic exploitation and job creation
WP 5 FI Support for transnational consortium building
WP 6 AT Human resources development and mobility
WP 7 HU Management concept and tools
WP 9 IL Science and society issues
WP 8 SP Implementing transnational activities
Contracts 1st roundContracts 2nd round
Month 0 24 604812 36
WP 2 DE Knowledge base for RTD strategies
WP 1 DE Status-quo of partner programmes
WP 10 DE Consortium management
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Deliverable No.: D 1.2 Information documents on the national programmes
Delivery date: due Month 5 (in January 2005)Nature: ReportDissemination level: PP
Aim: Basis for development of best practices in programme implementation and management
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Questionnaire: Survey on the national RTD programmes
Part A: General Programme Description:A1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statistics
Part B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Questionnaire: Survey on the national RTD landscape
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Preceding Programmes:no
Programme Name: GEN-AU – Austrian Genome Research Programme
Programme Owner: BMBWK – Federal Ministry of Education, Science and Culture
Programme Management Agency: Programme Office GEN-AU
Part of the larger Programme: no
Topic: genome research
Objective: e.g. enhance national competitiveness, strengthen research capacities, inprove conditions for investments
Start Year: 2001
End year: 2010
Further information: www.genomik.gen-au.at
Funding by:BMBWK 100%
Total No. of funded projects: 2 No. of running projects: 2
Funded by the Programme:- 2 Universities
- 1 public Research Institute
Total funding volume per year:10.0 mio € (2004)
(0.47 mio € Pathog.)Fixed Bugdet:
yes
A: General Programme Description AT
Next update / redesign: in process
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name: MICMAN – Microbes and Man
Programme Owner: Academy of Finland and The Swedish Foundation for Strategic Research
Programme Management Agency: National Public Health Institute
Part of the larger Programme: no
Topic: research on human-relevant microorganisms
Objective: increase the knowledge of the interaction between host and microbe and apply this knowledge
Start Year: 2003
End year: 2005
Further information: www.aka.fi/micman
Funding by:Research Academy 76%Private foundation 24%
Next update / redesign: none
Total No. of funded projects: 15No. of running projects: 15 ( 7 cons. of 2-4 Res. groups)
Funded by the Programme:- 7 Universities
- 2 public Research Institutes- 1 Regulatory Body
Preceding Programmes:no
Total funding volume per year:
1.8 mio €
Fixed Bugdet:yes
A: General Programme Description FI
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name:
Programme Owner:
Programme Management Agency:
Part of the larger Programme
Topic:
Objective:
Start Year:
End year:
Further information:
Funding by:- -
Total No. of funded projects: List of running projects:
Funded by the Programme:- - -
Preceeding Programmes:- -
A: General Programme Description FR
Next update / redesign:
8FixedBudget: yes/no
No data submitted
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Preceding Programmes:no
Programme Name: Competence Center PathoGenoMik
Programme Owner: BMBF – Federal Ministry of Education and Science
Programme Management Agency: PTJ
Part of the larger Programme: GenoMik (Genome Research in microorganisms)
Topic: genome research on bacteria (GenoMik)
Objective: use of the potential of microbial genomes for e.g. defeating human diseases
Start Year: 2001
End year: 2006
Further information: www.genomik.uni-wuerzburg.de
Funding by:BMBF (88.9%)
involved companies (11.1%)
Total No. of funded projects: 47 No. of running projects: 44
Funded by the Programme:- 13 Universities
- 2 Medical Centres- 4 public Research Institutes
- 6 Companies
Total funding volume per year:
3.63 mio € (BMBF)(2003)
Fixed Bugdet:yes
A: General Programme Description DE
Next update / redesign: none
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name:
Programme Owner:
Programme Management Agency:
Part of the larger Programme:
Topic:
Objective:
Start Year:
nd year:
Further information:
Funding by:
Total No. of funded projects: No. of running projects:
Funded by the Programme:
Preceding Programmes:
Total funding volume per year:
Fixed Bugdet:
A: General Programme Description HU
Next update / redesign:
No data submitted
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name: NA
Programme Owner: CSO-MOH – The Chief Scientist Office, Ministry of Health
Programme Management Agency: NA
Part of the larger Programme: no
Topic:
Objective:
Start Year: continous
End year: continuos
Further information: www.health.gov.il
Funding by:CSO-MOH 100%
Total No. of funded projects: 14 No. of running projects: 4
Funded by the Programme:- Universities
- Medical Centres- public Research Institutes
Preceding Programmes:no
Total funding volume per year:0.16 mio € (2003)
Fixed Bugdet:no
A: General Programme Description IL
Next update / redesign: none
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name: Molecular and epidemiological study of multiresistence and genetic variability of infections
Programme Owner: Latvian Council of Science
Programme Management Agency: NA
Part of the larger Programme NA
Topic:
Objective:
Start Year: 1998
End year: 2005
Further information: www.lzp.lv
Funding by:- LCS
Total No. of funded projects: 9 No. of running projects: 9
Funded by the Programme:- 100% Universities
Preceeding Programmes:- funct. Stability of microb. cultures-Genotoxicity by microorganisms-Mol. Studies on Borrellia burgd.
Total funding volume per year:
0,08 mio €
A: General Programme Description LV
Next update / redesign: 2005
Fixed Budget:yes
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name:
Programme Owner:
Programme Management Agency:
Part of the larger Programme
Topic:
Objective:
Start Year:
End year:
Further information:
Funding by:- -
Total No. of funded projects: List of running projects:
Funded by the Programme:- - -
Preceeding Programmes:- -
Total funding volume per year:
..mio €
A: General Programme Description PT
Next update / redesign:
FixedBudget: yes/no
No data submitted
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name: (10 different programmes)
Programme Owner: Ministry of Higher Education, Science and Technology
Programme Management Agency: programme managers in diverse institutions/Universities
Part of the larger Programme: national programme for financing research programmes
Topic: 1. target research programme 2. mol. Biology of microorganisms; pharmacolog. Chemistry; nutrition and ecology of gastroint. Tract; toxins and biomembranes etc.
Start Year: 2001 / 2004
End year: 2006 / 2008
Further information: website in slovenian language
Funding by:- 100% MESC- 47% MESC
- 47% Min. of Agric. For. + Food- 6% Min. of Health
Total No. of funded projects: 800 List of running projects: 450
Funded by the Programme:- 11 Universities
- 4 Medical Centers-39 Public Res. Inst.
-1 priv. res. Inst.-1 company
Preceeding Programmes:- No / yes
Total funding volume per year:0,496 mio € 2004(6th them. Prior.)
A: General Programme Description SV
Next update / redesign: 2006 / 2008
FixedBudget: no
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Name: 1. Strategic Action on Genomics and Proteomics
2. Biotechnology
Programme Owner: Ministry of Education and Science
Programme Management Agency: NA
Part of the larger Programme: National Plan of R&D
Topic: different topics (e.g. genomics, proteomics etc.)
Objective: functional analysis of genomes of human pathogens, characterisation of novel targets, pathogenicity mechanisms, host-pathogen-interactions, development of diagnostic tools
Start Year: 2004
End year: 2007
Further information: web site in national language
Funding by:MEC 100%
Total No. of funded projects: 56 No. of running projects: 31
Funded by the Programme:- 19 Universities
- 4 Medical Centres- 10 public Research Institutes
Preceding Programmes:Yes
National R&D plan 2000-03
Total funding volume per year:1.42 mio € (2004)
Fixed Bugdet:no
A: General Programme Description ES
Next update / redesign: 2007
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Next Programme update / redesign
Partner Update / redesign date
Austria In process
Finland No re-design
France
Germany Programme ends 2006; no update, but new programme
Hungary
Israel Continous programme
Latvia 2005
Portugal
Slovenia 2006
Spain 2007
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
who is funded by the programme?
0
10
20
30
40
50
60
Austria Finland Germany Israel Latvia Slovenia Slovenia Spain Spain
funded institutions
tota
l n
um
ber
of
fun
ded
in
stit
uti
on
s
other
companies
regulatory bodies
private research institutes
public research institutes
Medical Centers
Universities
funded Institutions
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Project Analysis (projects related to PatoGenoMics)
Austria 2 150 - 320 240 27
Partner Total no. of projects Range of annual budgets (1000 €)
Average annual project budget (1000 €)
Average duration of a project (months)
Finland 15 (7 consortia of
2-4 groups)
17 - 117 63 36
France
Germany 47 (9 project groups of 1-7 groups)
31 - 389 80 57
Hungary
Israel 14 15 - 29 15 12
Latvia 9 2 – 10 8 96
Portugal
Slovenia NA / 67 – 403 6 / 135 36 / 60
Spain 56 12 – 165 / 6 - 130 59 / 44 36 / 36
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme Design Process
Partner Top-down (idea was born and implemented by the funding authority)
Bottom-up (idea was born by others e.g. beneficiaries of funding)
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Programme / CallContents / text
First idea
MinistriesAT – BMBWKDE – BMBF
Scientific communities:AT, FI, IL, LV, SL, ES
Research councils AT, LV, SL
Editing of the Call text
Analysis Initiation phase:Who influencesthe programmedesign?
Boards/ institutions:• Scientific Advisory Board: AT, DE, LV• Research Councils: AT, LV, SL
Ministries/funding authorities/CommitteesAT – BMBWKFI – Steering Programme CommitteeDE – BMBFIL – CSO-MOHLV – Program leaderSL – Ministry of Science and
TechnologyES – MEC
influ
ence
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Electronical Application/Submission System
Partner Electr. System used
No electr. system
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Rules for Submission System obligatory optional
Austria Not available Paper Version
Finland Signature only Electr. System
France
Germany both
Hungary
Israel
Latvia
Portugal
Slovenia Not available Paper Version
Spain Electr. System
Partner Electr. System Paper Version Most common subm. way
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Application Support
Partner Written Manual Electronic guidance
Helpdesk / contact person
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Application Process: 1 step or 2 step approach
Partner 1 step-approach (full proposals) 2 step-approach (draft and full proposal
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Steps during Application• (draft proposal submission)• (draft proposal evaluation): AT, FI
Structure of draft: - Short description
of the project- Organisational and
scientific concept
Summary: Application / Submission Procedure
Support of applicants by:- Written manual: all except LV
- Electr. Guidance: all- Helpdesk/contact person: all
Approach: 2-stepDrafts + full proposals: AT, FI
Submission:-Electronically: FI, DE, IL, LV, ES
-paper: AT, FI, DE, IL, LV, SL
Elements of full proposals: - Name, coordinates, CV researcher(s)- scientific/technical description- Cost and time schedule- Management/organisation of networks- HR/ethical aspects- Relevance to programme- Relevance to industrial application
Approach: 1-stepfull proposals: DE, IL, LV, SL, ES
Rules of procedure by:- ministry: AT, DE, IL, SL, ES
- Academy/Council: FI, LV
• full proposal submission• full proposal evaluation: DE, IL, LV, SL, ES
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Is the call permanently open or are there cut-off dates?
Partner Permanently open (no direct competition of proposals)
Cut-off dates (direct competition of proposals)
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Partner Funding authority
External advisory board
Peer review Hearing of applicant
Presentation by applicant
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
Evaluation Process - Evaluation by:
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Evaluation Process: Stakeholders present among the evaluators
Partner Ministry
Manage-ment Agency
Research Council
Industry Organi-sation
Compa-ny
Single Scientist
Scientific Socie-ties
Experts from abroad
other
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Evaluator characteristics
Evaluators
• Evaluation by funding agency/authority: AT, FI, IL, LV, SL, ES• Evaluation by external advisory board: AT, FI, DE, SL, ES• Evaluation by peer review: AT, IL, SL
From Industry:AT, (IL), LV, ES
From abroad:AT, FI, DE, LV, ES
Standing board:DE, LV, SL
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Are the Evaluators known to the Applicants?
Partner yes no
Austria
Finland After the funding decision
France
Germany Some are known
Hungary
Israel Known post evaluation
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Can the final Evaluation result be overruled?
Partner yes no
Austria final decision is subject to the ministry
Finland final ranking by the programme Steering committee
France
Germany Evaluation may be overruled by the project management agency and the ministry
Hungary
Israel
Latvia Written complaint to Latvian Council of Science
Portugal
Slovenia Final decision by the funding bodies
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Evaluation criteria
5
2
5
7
21
13
3
13
7
5
15
7
14
19
910
4
0
5
10
15
20
25
Eth
ical
issu
es
Gen
der
issu
es
Inte
rnat
iona
l
com
petit
iven
ess
Inte
rnat
iona
lity
Inno
vativ
e
pote
ntia
l, no
velty
,
scie
ntifi
c re
cord
of a
pplic
ant
/ te
am
Mul
tidis
cipl
inar
itiy
pote
ntia
l of
appl
ican
t /
team
Pro
ject
/res
ourc
e
man
agem
ent
stan
dard
of
writ
ten
prop
osal
Rel
evan
ce t
o
indu
stria
l
Rel
evan
ce t
o
infr
astr
uctu
re
Rel
evan
ce t
o th
e
prog
ram
me
Sci
entif
ic q
ualit
y
of p
ropo
sal
Soc
ieta
l val
ue
Tra
inin
g as
pect
s
Tra
nsfe
r of
expe
rtis
e, m
obili
ty
sco
re
Analysis: Evaluation Criteria
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
imp. eval. criteria per country
0
5
10
15
20
25
most important evaluation criteria
sc
ore
Spain
Slovenia 2
Slovenia
Latvia
Israel
Germany
Finland
Austria
Analysis: most important Evaluation Criteria
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: most important evaluation criteria
Ranking Evaluation criteria Score points
1 Innovative potential, novelty, originality 21
2 Scientific quality of proposal 19
3 Relevance to industrial application and commercialisation
15
4 Relevance to the programme 14
5 potential of applicant / team 13
5 scientific record of applicant / team 13
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Partner Change of application/
evaluation procedure
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
Is it possible to change the rules of the application/evaluation procedure? possible impossible
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
0
2
4
6
8
10
12
14
Austri
a
Finlan
d
Germ
any
Israe
l
Latv
ia
Sloven
ia
Sloven
iaSpa
in
Partner
months
Time from funding notification offunding authority/agency till projectstart
Time from full proposal evaluation tillfunding notification of fundingauthority/agency
Time from full proposal submissiontill full proposal evaluation
Time from draft proposal evaluationtill full proposal submission
Time from draft proposal submissiontill draft proposal evaluation
Time from call publication to draft (full) proposal submission
How long does it take from publication of a call till start of a project?
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
40%from drafts
16%from drafts
23%
40%
16%
63%
0
10%
20%
30%
40%
50%
60%
70%
Austria Finland Germany Israel Latvia Slovenia Slovenia Spain Spain
project statistics: Average success rate of applications (drafts / full proposal versus funded projects)
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Funding possible impossible
Partner Synchronous calls with national funding
Joint calls with transnational funding
Austria
Finland
France
Germany
Hungary
Israel
Latvia
Portugal
Slovenia
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: cost models employed
Country AT FI FR DE HU IL LV PT SV ES
FCfull cost with actual indirect costs
FCFfull cost with indirect flat rate costs
ACadditional costs with indirect flat rate costs
other
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Country AT FI FR DE HU IL LV PT SV ES
Scientific/Technical Monitoring
Written reports 1/year 1/year 1/year 1/year 1/year 1/year 1/year
Oral reports/ interviews
1/year
Site visit
Seminar/conference 1/year 1/year 1/proj.
Administrative/financial Monitoring
Written reports 1/year 1-4/
year
6/year 2/year 1/year 1/year 1/year
Oral reports/ interviews
Site visit occasionally
Seminar/conference
Monitoring of ongoing projects
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of
programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Relative economic Importance of Antiinfektives (2003)
Partner Percentage of health expenses to GDP (%):
percentage of pharmaceuticals to total health expenses (%):
Total pharmaceutical retail market (maker’s price) (mio €):
Anti-Infectives pharmaceutical retail market
(mio €)
Austria
Finland
France
Germany 10,8 15,9 18.900 1.400 (7,4%)
Hungary
Israel 8,8 17,1 (1997)Latvia
Portugal
Slovenia 6,2 15,9 362 NASpain (2002) 7,6 22,0 12.976 821 (6,33%)
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Rank Germany Israel Slovenia Spain
1 RATIOPHARM (114) Teva Lek, d.d. (NA) GlaxoSmithKline
2 BAYER (104) Rafa Krka, d.d., Novo Mesto (0,29)
Aventis Pasteur MSD
3 PFIZER (96) Agis Esteve
4 AVENTIS (79) Farma Bayer
5 HEXAL (64) Lilly & Dista
6 GSK (51) Almirall Prodesfarma
7 ABBOTT (42) Farmacusi
8 FRESENIUS KAB.INTR (37)
Vita Group
9 MSD (33) Bohm
10 ASTRAZENECA (32)
Most important anti-infektives selling companies(antiinfektives sales per year in mio €)
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Results of the national pathogenomics RTD
landscape (expertise mapping etc.):
www.pathogenomics-era.net(internal pages)
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
A: General Programme Description
Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of programme and projects
Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Type of Research
basic; 7
applied; 7
Demonstration; 1 other ; 0
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA
XIII Aquifex
X Green Nonsulfur Bacteria
IX Deinococcus / Thermus
VIII Spirochaetes
I Proteobacteria
VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group
V Planctomyces, Pirella
IV Chlamydia
III Cyanobacteria
II Gram positive BacteriaXI Thermotoga
XII Thermo-desulfobacterium I Proteobacteria
II Gram positive Bacteria
IV Chlamydia
VIII Spirochaetes
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA
I Proteobacteria
IV Chlamydia
VIII Spirochaetes
XIII Aquifex
X Green Nonsulfur Bacteria
IX Deinococcus / Thermus
VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group
V Planctomyces, Pirella
III Cyanobacteria
XI Thermotoga
XII Thermo-desulfobacterium
II Gram positive Bacteria
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Organisms studied
I Proteobacteria
II Gram positive Bacteria
Gram-positive cocci: e.g. Staphylococcus, Streptococcus,Pneumococcus
Gram-positive non-sporulating rods: e.g. Listeria, Mycobacterium,
CorynebacteriumGram-positive sporulating rods: e.g. Bacillus, Clostridium
Gram-positive bacteria without cell wall: Mycoplasma
Gram-negative rods: e.g. E. coli, Salmonella, Yersinia, VibrioHaemophilus, Pasteurella, Helicobacter
Obligatory intracellular bacteria: Chlamydia
IV Chlamydia
VIII Spirochaetes Gram-negative spiral bacteria: e.g. Borellia, Treponema
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter
Gram + sporulating rodsBacillus, Clostridium
Gram + without cell wallMycoplasma
17
5
371
5
1015
33Gram + cocciStaphylococcus, Streptococcus
Gram + non-sporulating rodsListeria, Mycobacterium
Eukaryotic organismsfungi
Gram – spiral bacteriaBorrellia
obl. intracellular bacteriaChlamydia
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
Gram + sporulating rodsBacillus, Clostridium
Gram + without cell wallMycoplasma
17
5
371
5
1015
33Gram + cocciStaphylococcus, Streptococcus
Gram + non-sporulating rodsListeria, Mycobacterium
Eukaryotic organismsfungi
Gram – spiral bacteriaBorrellia
obl. intracellular bacteriaChlamydia
Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Gram-negative rods: which are the most common studied species?
E. Coli spec.
E. Coli ETEC (toxin producing)
E. Coli EHEC (enterohaemorragic)
Yersinia enteroliticaYersinia spec.
Salmonella typhi
Salmonella spec.
Shigella spec.
7
5
6
3
3
33
35Pseudomonas spec.
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Austria; 1Finland; 7
Germany; 20
Israel; 8
Latvia; 4
Slovenia; 0
Slovenia; 10
Spain; 11
Spain; 11
Austria
Finland
Germany
Israel
Latvia
Slovenia
Slovenia
Spain
Spain
Gram-negative rods: which are the most committed countries?
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter
Gram + sporulating rodsBacillus, Clostridium
Gram + without cell wallMycoplasma
17
5
371
5
1015
33Gram + cocciStaphylococcus, Streptococcus
Gram + non-sporulating rodsListeria, Mycobacterium
Eukaryotic organismsfungi
Gram – spiral bacteriaBorrellia
obl. intracellular bacteriaChlamydia
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
5
7
4
15
2
5
1
02
2 1
Staphylococcus spec.
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus spec.
Streptococcus pneumoniae
Streptococcus pyogenes
Pneumococcus spec.
Enterococcus spec.
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Austria; 2
Finland; 5
Germany; 10
Israel; 2Latvia; 3
Slovenia; 0
Slovenia; 6
Spain; 4
Spain; 4
Austria
Finland
Germany
Israel
Latvia
Slovenia
Slovenia
Spain
Spain
Gram-positive cocci: which are the most committed countries?
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter
Gram + sporulating rodsBacillus, Clostridium
Gram + without cell wallMycoplasma
17
5
371
5
1015
33Gram + cocciStaphylococcus, Streptococcus
Gram + non-sporulating rodsListeria, Mycobacterium
Eukaryotic organismsfungi
Gram – spiral bacteriaBorrellia
obl. intracellular bacteriaChlamydia
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Gram-positive non-sporulating rods : which are the most common studied species?
5
3
4
2
1
2
1
Listeria monocytogenes Streptomyces spec.
Mycobacterium spec. Mycobacterium tuberculosis
Mycobacterium bovis
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Gram-positive non-sporulating rods : which are the most committed countries?
Germany; 3
Israel; 1
Latvia; 2
Slovenia; 2Spain; 5
Spain; 5Austria
Finland
Germany
Israel
Latvia
Slovenia
Slovenia
Spain
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Organism groups studied
Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter
Gram + sporulating rodsBacillus, Clostridium
Gram + without cell wallMycoplasma
17
5
371
5
1015
33Gram + cocciStaphylococcus, Streptococcus
Gram + non-sporulating rodsListeria, Mycobacterium
Eukaryotic organismsfungi
Gram – spiral bacteriaBorrellia
obl. intracellular bacteriaChlamydia
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Eukaryotic Organisms: which are the most common studied ones?
Yeast 3
Aspergillus 4
Candida 2 Plasmodium 2
Leishmania 3
Echinococcus 1
other; 4 Yeast
Aspergillus
Candida
other (please specify):
- other:
Trypanosoma
Plasmodium
Leishmania
Echinococcus granulosus
other (please specify):
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Eukaryotic Organisms: which are the most committed countries?
Finland; 1
Israel; 3
Slovenia; 4
Spain; 5
Spain; 5 Austria
Finland
Germany
Israel
Latvia
Slovenia
Slovenia
Spain
Spain
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA
I Proteobacteria
XIII Aquifex
X Green Nonsulfur Bacteria
IX Deinococcus / Thermus
VIII Spirochaetes
VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group
V Planctomyces, Pirella
IV Chlamydia
III Cyanobacteria
II Gram positive BacteriaXI Thermotoga
XII Thermo-desulfobacterium
Alpha: e.g. Acetobacter, Agrobacterium, Gluconobacter, Paracoccus, Rhodospirillum,Rhizobium, Zymomonas
Beta: e.g. Neisseria, Pseudomonas (some), Spirillum
Gamma: e.g. Escherichia, Legionella, Salmonella and other intestine bacteria, Vibrio
Delta: e.g. sulfate reducing bacteria, Myxobacteria, Xanthomonas (some)
Epsilon: e.g. Campylobacter, Helicobacter, Xanthomonas (some)
ERA-NET PathoGenoMics
M. Karrasch, FZJ13.01.2005
WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape
II Gram positive Bacteria
Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA
XIII Aquifex
X Green Nonsulfur Bacteria
IX Deinococcus / Thermus
VIII Spirochaetes
I Proteobacteria
VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group
V Planctomyces, Pirella
IV Chlamydia
III Cyanobacteria
XI Thermotoga
XII Thermo-desulfobacterium I Proteobacteria
Non sporulating gram+ bacteria, low G+C content:e.g. Staphylococcus, Streptococcus, Micrococcus, Lactobacillus, Enterococcus, Listeria
Endosporulating gram+ bacteria, low G+C content: e.g. Bacillus, Clostridium
Bacteria without cell wall: Mycoplasma
gram+ bacteria, high G+C content:e.g. Corynebacterium, Mycobacterium, Actinomycetes